Literature DB >> 17066436

Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers.

Yoon-Jung Boo1, Sung-Soo Park, Jong-Han Kim, Young-Jae Mok, Seong-Joo Kim, Chong-Suk Kim.   

Abstract

BACKGROUND AND OBJECTIVES: Gastric neuroendocrine carcinoma (NEC) is an uncommon cancer of the stomach. The classification of NEC and its clinical behavior remains controversial, and prognostic markers and their therapeutic guidelines have not been clearly defined. The aim of this study was to evaluate the clinicopathologic characteristics of these tumors and analyze the expression of E-cadherin and Ki-67 as prognostic markers in gastric NECs.
METHODS: We retrospectively reviewed 17 cases of gastric NECs. Tumor pathology was reviewed and the tumors were categorized as well-differentiated NEC (n = 5) and poorly differentiated NEC (n = 12) according to the WHO classification. With the aim of evaluating the expression of E-cadherin and Ki-67 and their prognostic role in gastric NEC, immunohistochemical analysis of the tumors was performed.
RESULTS: The median survival of patients was 20.0 months (95% confidence interval (CI), 13.2-28.8). There was a statistically significant difference in overall survival between well and poorly differentiated NECs (P = 0.021). However, there was no significant difference in overall survival between patients with poorly differentiated small cell and large cell NEC (P = 0.796). Loss of E-cadherin was correlated with lymph node metastasis (P= 0.044). A high Ki-67 proliferation index (PI) (>60%) was correlated with tumor recurrence (P = 0.013) and histologic differentiation (P= 0.028).
CONCLUSIONS: Loss of E-cadherin may predict lymph node metastasis in gastric NECs. A high Ki-67 PI (>60%) could be used as a prognostic marker to predict aggressive gastric NECs in addition to standard pathologic classification. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17066436     DOI: 10.1002/jso.20616

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  13 in total

1.  Simultaneous large cell neuroendocrine carcinoma and adenocarcinoma of the stomach.

Authors:  Tadashi Terada; Hirotoshi Maruo
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

2.  Endocrine carcinoma of the stomach: clinicopathological analysis of 27 surgically treated cases in a single institute.

Authors:  Takeshi Kubota; Shigekazu Ohyama; Naoki Hiki; Souya Nunobe; Noriko Yamamoto; Toshiharu Yamaguchi
Journal:  Gastric Cancer       Date:  2012-01-18       Impact factor: 7.370

3.  Large-cell neuroendocrine carcinoma of the ampulla of Vater.

Authors:  Z Stojsic; D Brasanac; D Bilanovic; O Mitrovic; R Stevanovic; I Boricic
Journal:  Med Oncol       Date:  2009-11-07       Impact factor: 3.064

4.  Neuroendocrine carcinoma of the stomach: clinicopathological and immunohistochemical evaluation.

Authors:  Tsutomu Namikawa; Toyokazu Oki; Hiroyuki Kitagawa; Takehiro Okabayashi; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Med Mol Morphol       Date:  2013-01-10       Impact factor: 2.309

5.  Prognostic value of immunohistochemical factors in esophageal small cell carcinoma (ESCC): analysis of clinicopathologic features of 73 patients.

Authors:  Yigong Zhang; Cong Li; Ming Chen
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

6.  Immunohistochemical consistency between primary tumors and lymph node metastases of gastric neuroendocrine carcinoma.

Authors:  Chieko Uchiyama; Shigeyuki Tamura; Shinichi Nakatsuka; Atsushi Takeno; Hirofumi Miki; Takashi Kanemura; Shin Nakahira; Rei Suzuki; Ken Nakata; Yutaka Takeda; Takeshi Kato
Journal:  World J Surg Oncol       Date:  2012-06-22       Impact factor: 2.754

Review 7.  Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review.

Authors:  Emma Elizabeth Ilett; Seppo W Langer; Ingrid Holst Olsen; Birgitte Federspiel; Andreas Kjær; Ulrich Knigge
Journal:  Diagnostics (Basel)       Date:  2015-04-08

8.  Clinicopathological Features and Prognostic Factors of Colorectal Neuroendocrine Neoplasms.

Authors:  Mengjie Jiang; Yinuo Tan; Xiaofen Li; Jianfei Fu; Hanguang Hu; Xianyun Ye; Ying Cao; Jinghong Xu; Ying Yuan
Journal:  Gastroenterol Res Pract       Date:  2017-01-17       Impact factor: 2.260

9.  Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms.

Authors:  Alexander Koenig; Sebastian Krug; Daniela Mueller; Peter J Barth; Ute Koenig; Michael Scharf; Volker Ellenrieder; Patrick Michl; Roland Moll; Kia Homayunfar; Peter Herbert Kann; Philipp Stroebel; Thomas M Gress; Anja Rinke
Journal:  PLoS One       Date:  2017-12-12       Impact factor: 3.240

10.  Histological characterisation and prognostic evaluation of 62 gastric neuroendocrine carcinomas.

Authors:  Yujie Deng; Xiaohui Chen; Yuhong Ye; Xi Shi; Kunshou Zhu; Liming Huang; Sheng Zhang; Mingang Ying; Xuede Lin
Journal:  Contemp Oncol (Pozn)       Date:  2016-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.